Daily Reporter

Today Don't Miss

Today Don't Miss

Are we reaching a turning point in metastatic prostate cancer?

At yesterday’s Presidential Symposium, a Late-Breaking Abstract presentation of the PROfound study reported a clinically meaningful benefit in radiological progression-free survival (PFS) with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant…

Read More


Precision medicine bursts onto the biliary tract cancer scene

The management of biliary tract cancers, especially cholangiocarcinoma, is rapidly changing with emerging new precision medicine strategies. “Most research is focused on patients harbouring fibroblast growth factor receptor-2 (FGFR2) fusions and isocitrate dehydrogenase-1 (IDH1) mutations,…

Read More



Translating science into better cancer care

Starting today in Barcelona, Spain, the ESMO Congress 2019 aims to focus on novel approaches and breakthroughs that can drive advances along the three-stage course of cancer care, from laboratories to clinical settings and from…

Watch Here

Adding FOLFIRINOX to nab-PG may improve outcomes in pancreatic cancer

“Patients with locally advanced pancreatic cancer must be treated with combination chemotherapy and, until proven otherwise, valid options are FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) and nab-paclitaxel plus gemcitabine (nab-PG). The latter followed by FOLFIRINOX is…

Read More